HC Wainwright & Co. Maintains Buy Rating for BioLine Rx: Here’s What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of BioLine Rx (NASDAQ:BLRX) and raise its…
Unity Software To Rally Around 60%? Here Are 10 Other Analyst Forecasts For Friday
B of A Securities raised the price target for Unity Software Inc. (NYSE: U) from $46 to $56. B of A Securities analyst Ryan Gee upgraded the stock from Neutral to Buy. Unity Software shares fell 3% to close at $35.71 on Thursday.
Earnings Scheduled For August 30, 2023
Companies Reporting Before The Bell
• Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its second quarter.
A Preview Of BioLine Rx’s Earnings
BioLine Rx (NASDAQ:BLRX) is set to give its latest quarterly earnings report on Wednesday, 2023-08-30. Here’s what investors…
Earnings Scheduled For May 24, 2023
Companies Reporting Before The Bell
• Bank of Nova Scotia (NYSE:BNS) is estimated to report quarterly earnings at $1.78 per share on revenue of $8.09 billion.
BioLineRx Announces Publication In Nature Medicine Of Its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide And G-CSF In Stem Cell Mobilization For Autologous Transplantation In Multiple Myeloma
- GENESIS trial achieved statistical significance (p<0.0001) across all primary and secondary endpoints -
- Nature Medicine publication describes how GENESIS trial included patients representative of current
Biokine Therapeutics Ltd., BioLineRx Ltd. Granted U.S. Patent #11554159: Compositions And Methods For Treating Cancer
https://www.scribd.com/document/620316827/BLRX-Patent
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 53.2% to $0.31 during Thursday’s after-market session. Today’s trading volume…
12 Health Care Stocks Moving In Friday’s Pre-Market Session
Gainers Immuron (NASDAQ:IMRN) stock increased by 42.2% to $2.29 during Friday’s pre-market session. The company’s market cap stands…
BioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidate
BioLineRx Ltd (NASDAQ:BLRX) announced results from the Phase 1/2a study of the intratumoral cancer vaccine candidate AGI-134 in patients with unresectable…